0.48
—
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mabpharm
Its shares trade on HKEX under the ticker 2181.HK. It has been listed since 31 May 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥629.4m and net income of CN¥55.7m. At that date it held total assets of CN¥1.15bn and shareholders' equity of CN¥157.4m.
Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-05-31. The firm's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The firm mainly conducts its businesses in China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 May 2019
- Employees
- 308
- Website
- mabpharm.cn ↗
Leadership
Pay as last reported
- Mr. Shuge JiaoNon-Executive Chairman of the Board
- Dr. Hao WangChief Scientific Officer, Executive Director, since 2018CN¥5.2m
- Mr. Yunfeng LiVice President, Executive Director, since 2018CN¥1.5m
- Dr. Weizhu QianVice President, Executive Director, since 2023
- Mr. Wenhui ZhugeVice President of Sales
- Dr. Sheng HouExecutive Director, since 2023
- Mr. Jing TaoExecutive Director, since 2020CN¥1.4m
- Mr. Ho Yin TsangJoint Company Secretary
- Mr. Jialin CenNon-Executive Director
- Mr. Liangzhong GuoNon-Executive Independent DirectorCN¥98,000
- Mr. Ho Ming LeungNon-Executive Independent Director
- Dr. Qian TaoNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mabpharm Ltd possesses strong research and development capabilities, allowing them to develop innovative and high-quality pharmaceutical products. Their expertise in biotechnology gives them a competitive edge in the market.
- The company has a diversified product portfolio, offering a wide range of medications for various therapeutic areas. This diversification helps them cater to different market segments and reduce their dependence on a single product.
Weaknesses
- Mabpharm Ltd is relatively small in size compared to some of its competitors, limiting its resources and market reach. This may pose challenges in terms of scaling up production, marketing, and distribution.
- The company heavily relies on a few key suppliers for raw materials, which could potentially impact their supply chain if any issues arise with these suppliers.
Opportunities
- The growing demand for personalized medicine provides an opportunity for Mabpharm Ltd to develop and market targeted therapies, leveraging their expertise in biotechnology. This can help them differentiate themselves in the market.
- Expansion into emerging markets, especially in Asia and Latin America, can open up new revenue streams for the company. These regions are experiencing rapid economic growth and an increasing demand for pharmaceutical products.
Threats
- Intense competition from larger pharmaceutical companies with greater resources and established market presence poses a threat to Mabpharm Ltd. They need to continuously innovate and differentiate themselves to stay competitive.
- Government regulations and policies related to drug pricing and approvals can impact the company's operations and profitability. Adapting to changing regulatory environments is crucial for sustained success.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.